Hepatitis C cure with antiviral therapy--benefits beyond the liver
Liver disease is the major complication of chronic HCV infection. However, extrahepatic complications are common (50-75%), including mixed cryoglobulinaemia and B-cell lymphomas. Given that chronic hepatitis C has become curable using expensive oral direct-acting antivirals (DAAs), it seems worth revisiting the whole spectrum and burden of disease in HCV carriers.Herein, we update the most clinically significant medical complications associated with chronic hepatitis C and the evidence of benefits that would derive from a wide use of curative DAA therapies.Chronic HCV infection is associated with a broad spectrum of clinical conditions, including distinct rheumatic disorders (polyarthritis, sicca syndrome), lymphoproliferative conditions (mixed cryoglobulinaemia, monoclonal gammapathies and B-cell lymphomas) and damage at other organs due to persistent systemic inflammation, leading to renal, bone, neurological and/or cardiovascular disease. Eradication of HCV with DAAs is associated with amelioration and/or resolution of most liver-related and extrahepatic complications. Ultimately, gains in quality of life and survival favour treating everyone with hepatitis C regardless of liver fibrosis stage.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
Antiviral therapy - 21(2016), 1 vom: 15., Seite 1-8 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Soriano, Vincent [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antiviral Agents |
|---|
| Anmerkungen: |
Date Completed 13.12.2016 Date Revised 30.12.2016 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3851/IMP2975 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM250304287 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM250304287 | ||
| 003 | DE-627 | ||
| 005 | 20231224155438.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3851/IMP2975 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0834.xml |
| 035 | |a (DE-627)NLM250304287 | ||
| 035 | |a (NLM)26110692 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Soriano, Vincent |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Hepatitis C cure with antiviral therapy--benefits beyond the liver |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.12.2016 | ||
| 500 | |a Date Revised 30.12.2016 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Liver disease is the major complication of chronic HCV infection. However, extrahepatic complications are common (50-75%), including mixed cryoglobulinaemia and B-cell lymphomas. Given that chronic hepatitis C has become curable using expensive oral direct-acting antivirals (DAAs), it seems worth revisiting the whole spectrum and burden of disease in HCV carriers.Herein, we update the most clinically significant medical complications associated with chronic hepatitis C and the evidence of benefits that would derive from a wide use of curative DAA therapies.Chronic HCV infection is associated with a broad spectrum of clinical conditions, including distinct rheumatic disorders (polyarthritis, sicca syndrome), lymphoproliferative conditions (mixed cryoglobulinaemia, monoclonal gammapathies and B-cell lymphomas) and damage at other organs due to persistent systemic inflammation, leading to renal, bone, neurological and/or cardiovascular disease. Eradication of HCV with DAAs is associated with amelioration and/or resolution of most liver-related and extrahepatic complications. Ultimately, gains in quality of life and survival favour treating everyone with hepatitis C regardless of liver fibrosis stage | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 700 | 1 | |a Labarga, Pablo |e verfasserin |4 aut | |
| 700 | 1 | |a Fernandez-Montero, José V |e verfasserin |4 aut | |
| 700 | 1 | |a de Mendoza, Carmen |e verfasserin |4 aut | |
| 700 | 1 | |a Esposito, Isabella |e verfasserin |4 aut | |
| 700 | 1 | |a Benítez-Gutiérrez, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Barreiro, Pablo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Antiviral therapy |d 1996 |g 21(2016), 1 vom: 15., Seite 1-8 |w (DE-627)NLM097535710 |x 2040-2058 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2016 |g number:1 |g day:15 |g pages:1-8 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3851/IMP2975 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2016 |e 1 |b 15 |h 1-8 | ||